CRIS Current Research Information System

RIZZO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.511
NA - Nord America 3.808
EU - Europa 2.054
Continente sconosciuto - Info sul continente non disponibili 280
SA - Sud America 235
AF - Africa 210
OC - Oceania 4
Totale 11.102
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.717
SG - Singapore 1.316
CN - Cina 1.200
VN - Vietnam 908
IT - Italia 554
HK - Hong Kong 345
SE - Svezia 297
DE - Germania 234
KR - Corea 195
GB - Regno Unito 194
BR - Brasile 166
IN - India 153
CH - Svizzera 127
IE - Irlanda 110
BD - Bangladesh 109
FR - Francia 105
NL - Olanda 103
FI - Finlandia 102
RU - Federazione Russa 85
CI - Costa d'Avorio 67
CA - Canada 48
JP - Giappone 48
SC - Seychelles 48
ID - Indonesia 46
PH - Filippine 31
JO - Giordania 30
TG - Togo 26
TR - Turchia 26
BG - Bulgaria 25
AR - Argentina 24
ZA - Sudafrica 24
AT - Austria 23
TH - Thailandia 20
NG - Nigeria 18
MX - Messico 17
PL - Polonia 17
GR - Grecia 14
IQ - Iraq 14
UA - Ucraina 13
ES - Italia 11
CO - Colombia 10
PK - Pakistan 10
BE - Belgio 8
EC - Ecuador 8
LT - Lituania 8
VE - Venezuela 8
CL - Cile 7
PS - Palestinian Territory 7
TW - Taiwan 7
MY - Malesia 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
CR - Costa Rica 5
IR - Iran 5
MA - Marocco 5
PY - Paraguay 5
HN - Honduras 4
IL - Israele 4
KE - Kenya 4
PE - Perù 4
AU - Australia 3
CD - Congo 3
HU - Ungheria 3
JM - Giamaica 3
KZ - Kazakistan 3
NI - Nicaragua 3
SA - Arabia Saudita 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
TN - Tunisia 3
AZ - Azerbaigian 2
BY - Bielorussia 2
CY - Cipro 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EG - Egitto 2
ET - Etiopia 2
GH - Ghana 2
GT - Guatemala 2
LB - Libano 2
LV - Lettonia 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CG - Congo 1
CZ - Repubblica Ceca 1
EE - Estonia 1
FJ - Figi 1
GE - Georgia 1
HR - Croazia 1
HT - Haiti 1
KG - Kirghizistan 1
Totale 10.812
Salva come PNG Salva come JPEG
Città #
Singapore 911
Ashburn 386
Hefei 374
Hong Kong 323
San Jose 302
Dallas 257
Chandler 226
Ho Chi Minh City 218
Hanoi 207
Council Bluffs 188
Boardman 173
Seoul 171
Beijing 159
Santa Clara 159
Bern 124
Southend 122
Bologna 117
Fairfield 116
Dublin 110
Princeton 107
Dong Ket 96
Los Angeles 95
New York 77
Helsinki 71
Abidjan 67
Lauterbourg 65
Houston 51
Buffalo 49
Milan 47
Redondo Beach 45
Redmond 41
Woodbridge 41
Seattle 40
Guangzhou 37
Frankfurt am Main 36
Haiphong 35
Bengaluru 34
Tokyo 34
Jakarta 33
Wilmington 33
Boydton 32
Chicago 32
Amman 30
São Paulo 30
Cambridge 29
Lomé 26
Shanghai 26
Da Nang 25
London 25
Rome 25
Florence 24
Berlin 23
Lappeenranta 22
Turin 22
Munich 19
Sofia 19
San Diego 17
Phoenix 16
Shenzhen 16
Nuremberg 15
Orem 15
Biên Hòa 14
Brooklyn 14
Medford 14
Tongling 14
Washington 14
Abeokuta 13
Amsterdam 13
San Francisco 13
Vienna 13
Atlanta 12
Denver 12
Hải Dương 12
Can Tho 11
Castel Maggiore 11
Changsha 11
Istanbul 11
Nanjing 11
Toronto 11
Johannesburg 10
Montreal 10
Philadelphia 10
Zhengzhou 10
Des Moines 9
Mexico City 9
Stockholm 9
Tân Tiến 9
Warsaw 9
Ann Arbor 8
Brussels 8
Cape Town 8
Charlotte 8
Chennai 8
Hyderabad 8
Madrid 8
Olalla 8
Poplar 8
Xi'an 8
Bari 7
Chongqing 7
Totale 6.668
Salva come PNG Salva come JPEG
Nome #
Adjuvant treatment in biliary tract cancer 347
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 306
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 236
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 231
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 220
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 211
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 210
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 204
Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile 200
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 199
The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST) 196
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 188
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 188
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma 182
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 179
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 171
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 170
Bone targeting agents in patients with metastatic prostate cancer: State of the art 169
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 167
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 165
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 164
Hacking pancreatic cancer: Present and future of personalized medicine 163
Skull Metastasis From Uterine Leiomyosarcoma, a Rare Presentation for a Rare Tumor: A Case Report and Review of the Literature 161
Third-and later-line treatment in advanced or metastatic gastric cancer: A systematic review and meta-analysis 157
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 155
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 153
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 146
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis 144
Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis 144
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review 144
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 138
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors 130
Experimental HER2- targeted therapies for biliary tract cancer 130
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials 128
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 128
Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions 126
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 113
Metabolomic profiling in renal cell carcinoma patients: News and views 112
Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer 111
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis 111
Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report 111
Novel HER2-directed treatments in advanced gastric carcinoma: Another paradigm shift? 111
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study 106
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents 101
Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms 99
Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer 95
Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art 92
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue 89
Cancer immunotherapy: Current and future perspectives on a therapeutic revolution 87
Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma 87
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 86
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!” 83
Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis 82
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 81
Second-line FOLFOX chemotherapy for advanced biliary tract cancer 81
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 79
Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis 79
Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives 79
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives 78
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer 78
BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care 77
Microbiota and prostate cancer 73
Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis 73
TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks 72
Cabozantinib for Treatment of Brain Metastases in Patients with Renal Cell Carcinoma 71
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? 71
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 70
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): A new Pandora's box? 67
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis 66
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis 66
Atezolizumab in advanced hepatocellular carcinoma: Good things come to those who wait 63
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? 62
Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? 62
The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: Will immunotherapy solve the problem? 60
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma 59
Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: A meta-analysis 58
Novel targeted therapies for advanced cholangiocarcinoma 58
Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies 58
Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma 56
DNA damage response alterations in gastric cancer: Knocking down a new wall 56
Recent advances of immunotherapy for biliary tract cancer 53
Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis 51
In Regard to “A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)” 50
Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis 48
Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis 47
Systemic adjuvant treatment in hepatocellular carcinoma: Tempted to do something rather than nothing 46
A brand-new CAR for macrophages: Is it time to fire up the engines of a new era for the treatment of renal cell carcinoma? 45
Toward personalized therapy for cholangiocarcinoma: new insights and challenges 45
Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer 45
Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma 44
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 43
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study 43
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 42
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 41
Regarding “HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer” 39
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma 39
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study 36
Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma 36
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 34
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma 34
Totale 10.840
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.166
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.166
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022715 0 11 23 42 39 17 16 50 173 54 183 107
2022/20231.462 97 132 60 106 148 163 63 92 223 66 107 205
2023/2024417 67 71 32 29 25 65 14 22 15 36 20 21
2024/20252.011 85 251 232 141 231 87 147 88 32 112 191 414
2025/20265.540 476 546 715 423 476 241 519 250 908 444 295 247
2026/2027417 192 225 0 0 0 0 0 0 0 0 0 0
Totale 11.102